DLBCL-话题@MedSci

#DLBCL#

52篇内容 | 3298人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2201081, encodeId=55cf2201081d5, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a> <a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a> <a href='/topic/show?id=ab2023868f8' target=_blank style='color:#2F92EE;'>#二代测序#</a> <a href='/topic/show?id=c61a113994dc' target=_blank style='color:#2F92EE;'>#LymphGen#</a>, objectTitle=Haematologica：通过二代测序验证DLBCL的LymphGen分类系统, objectType=article, longId=823819, objectId=c14b8238192c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=c14b8238192c, replyNumber=0, likeNumber=155, createdTime=2024-04-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c14b8238192c, moduleTitle=Haematologica：通过二代测序验证DLBCL的LymphGen分类系统, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c14b8238192c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2200406, encodeId=e681220040627, content=<a href='/topic/show?id=f76e15029a7' target=_blank style='color:#2F92EE;'>#R-CHOP#</a> <a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a> <a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=【Cancer Med】各治疗线DLBCL的真实世界患者特征、治疗模式和结局, objectType=article, longId=823169, objectId=d3a6823169df, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-examining-medical-report-PJUYHWX.jpg, objectUrl=/article/show_article.do?id=d3a6823169df, replyNumber=0, likeNumber=156, createdTime=2024-04-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=d3a6823169df, moduleTitle=【Cancer Med】各治疗线DLBCL的真实世界患者特征、治疗模式和结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3a6823169df)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2198818, encodeId=84b321988188a, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=206e112102dd' target=_blank style='color:#2F92EE;'>#复发/难治性大B细胞淋巴瘤#</a>, objectTitle=Haematologica：760例不同亚型LBCL接受CAR-T治疗的结局, objectType=article, longId=821691, objectId=861e82169128, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696894916699_4754896.jpeg, objectUrl=/article/show_article.do?id=861e82169128, replyNumber=0, likeNumber=118, createdTime=2024-04-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=861e82169128, moduleTitle=Haematologica：760例不同亚型LBCL接受CAR-T治疗的结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861e82169128)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2195811, encodeId=6e9c219581176, content=<a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=CAR-T治疗高端B细胞患者有批次, objectType=article, longId=818041, objectId=8b4f81804160, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301009/1696894905510_4754896.jpeg, objectUrl=/article/show_article.do?id=8b4f81804160, replyNumber=0, likeNumber=78, createdTime=2024-03-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=8b4f81804160, moduleTitle=CAR-T治疗高端B细胞患者有批次, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b4f81804160)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188279, encodeId=609b21882e9cb, content=<a href='/topic/show?id=f76e15029a7' target=_blank style='color:#2F92EE;'>#R-CHOP#</a> <a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=【Cancer Treat Rev】DLBCL中改良R-CHOP的路线图, objectType=article, longId=813728, objectId=ecfb813e2824, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-working-at-the-hospital-PAJM2K5.jpg, objectUrl=/article/show_article.do?id=ecfb813e2824, replyNumber=0, likeNumber=97, createdTime=2024-02-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ecfb813e2824, moduleTitle=【Cancer Treat Rev】DLBCL中改良R-CHOP的路线图, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecfb813e2824)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2185098, encodeId=637021850981b, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a> <a href='/topic/show?id=141d40627a' target=_blank style='color:#2F92EE;'>#CAR-T#</a> <a href='/topic/show?id=567650039e9' target=_blank style='color:#2F92EE;'>#弥漫大B细胞淋巴瘤#</a>, objectTitle=【EHO】R/R DLBCL患者CAR-T治疗失败后异基因移植的结局, objectType=article, longId=811709, objectId=0513811e0928, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing-D3K6QME.jpg, objectUrl=/article/show_article.do?id=0513811e0928, replyNumber=0, likeNumber=107, createdTime=2024-01-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=0513811e0928, moduleTitle=【EHO】R/R DLBCL患者CAR-T治疗失败后异基因移植的结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0513811e0928)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2184181, encodeId=c11c21841813c, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a> <a href='/topic/show?id=567650039e9' target=_blank style='color:#2F92EE;'>#弥漫大B细胞淋巴瘤#</a>, objectTitle=【Cancer Lett】CD30在EBV+DLBCL中高表达的调控机制及其影响预后的分子机制, objectType=article, longId=811053, objectId=c32281105373, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016299208_4754896.png, objectUrl=/article/show_article.do?id=c32281105373, replyNumber=0, likeNumber=117, createdTime=2024-01-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=c32281105373, moduleTitle=【Cancer Lett】CD30在EBV+DLBCL中高表达的调控机制及其影响预后的分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c32281105373)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183684, encodeId=433c21836842b, content=<a href='/topic/show?id=576a653899d' target=_blank style='color:#2F92EE;'>#流行病学#</a> <a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a> <a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=【Semin Hematol】弥漫性大B细胞淋巴瘤的流行病学和病原学, objectType=article, longId=810723, objectId=8d3b810e23ea, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/filling-medical-history-XZB9RVX.jpg, objectUrl=/article/show_article.do?id=8d3b810e23ea, replyNumber=0, likeNumber=112, createdTime=2024-01-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=8d3b810e23ea, moduleTitle=【Semin Hematol】弥漫性大B细胞淋巴瘤的流行病学和病原学, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d3b810e23ea)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2181171, encodeId=405f21811e1c4, content=<a href='/topic/show?id=dfac433ed7' target=_blank style='color:#2F92EE;'>#CD47#</a> <a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a> <a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=【Clin Transl Med】赵维莅教授团队证实CD47过表达与DLBCL微环境和进展的关系, objectType=article, longId=808927, objectId=c1e680892e5d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=c1e680892e5d, replyNumber=0, likeNumber=122, createdTime=2024-01-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=c1e680892e5d, moduleTitle=【Clin Transl Med】赵维莅教授团队证实CD47过表达与DLBCL微环境和进展的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e680892e5d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1360526, encodeId=8ee11360526ae, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性, objectType=article, longId=739080, objectId=9bbfe3908038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bbfe3908038, replyNumber=0, likeNumber=109, createdTime=2022-09-13, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bbfe3908038, moduleTitle=ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9bbfe3908038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360525, encodeId=6c2e1360525ea, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, objectType=article, longId=739079, objectId=dbbfe390796d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbbfe390796d, replyNumber=0, likeNumber=97, createdTime=2022-09-13, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbbfe390796d, moduleTitle=ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbbfe390796d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360524, encodeId=c7db13605249e, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood Cancer J：R-CEOP是不适合蒽环类DLBCL患者一线治疗的首选？, objectType=article, longId=738648, objectId=b946e386483e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b946e386483e, replyNumber=0, likeNumber=108, createdTime=2022-09-10, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b946e386483e, moduleTitle=Blood Cancer J：R-CEOP是不适合蒽环类DLBCL患者一线治疗的首选？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b946e386483e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360523, encodeId=c48d13605236d, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=≥70岁DLBCL患者的临床特征和生存结局，来自中国多中心研究, objectType=article, longId=735555, objectId=9b73e35555dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b73e35555dd, replyNumber=0, likeNumber=81, createdTime=2022-08-12, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b73e35555dd, moduleTitle=≥70岁DLBCL患者的临床特征和生存结局，来自中国多中心研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b73e35555dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360522, encodeId=65f21360522a2, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=【Blood Adv】rrDLBCL患者的基因突变谱及对CAR-T治疗的疗效, objectType=article, longId=734616, objectId=122ee346162f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=122ee346162f, replyNumber=0, likeNumber=74, createdTime=2022-08-06, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=122ee346162f, moduleTitle=【Blood Adv】rrDLBCL患者的基因突变谱及对CAR-T治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=122ee346162f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360521, encodeId=0ead1360521b6, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=ASH 2021：二线 Axicabtagene Cilouleucel 治疗复发/难治DLBCL，疗效更佳, objectType=article, longId=292794, objectId=003b292e949c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=003b292e949c, replyNumber=0, likeNumber=95, createdTime=2021-12-28, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=003b292e949c, moduleTitle=ASH 2021：二线 Axicabtagene Cilouleucel 治疗复发/难治DLBCL，疗效更佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=003b292e949c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360520, encodeId=56101360520ed, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Blood Cancer J：大剂量甲氨蝶呤可有效预防DLBCL患者孤立性CNS复发, objectType=article, longId=216228, objectId=5cf7216228e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cf7216228e4, replyNumber=0, likeNumber=110, createdTime=2021-08-25, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cf7216228e4, moduleTitle=Blood Cancer J：大剂量甲氨蝶呤可有效预防DLBCL患者孤立性CNS复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cf7216228e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360519, encodeId=88411360519e2, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=瑞基仑赛（Relma-cel）对于R/R DLBCL患者表现出突破性疗效, objectType=article, longId=214742, objectId=fde0214e427b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fde0214e427b, replyNumber=0, likeNumber=112, createdTime=2021-07-26, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fde0214e427b, moduleTitle=瑞基仑赛（Relma-cel）对于R/R DLBCL患者表现出突破性疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fde0214e427b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360518, encodeId=87b7136051837, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Int J Clin Oncol：tisagenlecleucel可有效且安全的治疗某些特定的日本R/R DLBCL患者, objectType=article, longId=212391, objectId=3ae121239168, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ae121239168, replyNumber=0, likeNumber=86, createdTime=2021-06-08, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ae121239168, moduleTitle=Int J Clin Oncol：tisagenlecleucel可有效且安全的治疗某些特定的日本R/R DLBCL患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ae121239168)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360517, encodeId=19fb136051eae, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, objectType=article, longId=211832, objectId=fc31211832f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31211832f6, replyNumber=0, likeNumber=94, createdTime=2021-05-27, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31211832f6, moduleTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31211832f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1360516, encodeId=f44a136051646, content=<a href='/topic/show?id=e58d60299c' target=_blank style='color:#2F92EE;'>#DLBCL#</a>, objectTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, objectType=article, longId=211283, objectId=6e722112837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e722112837b, replyNumber=0, likeNumber=75, createdTime=2021-05-15, rootId=0, userName=cathymary, userId=226a143, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e722112837b, moduleTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e722112837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

DLBCL

2020-05-29

梅斯管理员

#弥漫性大B细胞淋巴瘤# #DLBCL# #二代测序# #LymphGen#

Haematologica：通过二代测序验证DLBCL的LymphGen分类系统

2024-04-29发表于上海

梅斯管理员

#R-CHOP# #弥漫性大B细胞淋巴瘤# #DLBCL#

【Cancer Med】各治疗线DLBCL的真实世界患者特征、治疗模式和结局

2024-04-25发表于陕西省

梅斯管理员

#DLBCL# #CAR-T# #复发/难治性大B细胞淋巴瘤#

Haematologica：760例不同亚型LBCL接受CAR-T治疗的结局

2024-04-16发表于上海

梅斯管理员

#CAR-T# #DLBCL#

CAR-T治疗高端B细胞患者有批次

2024-03-28发表于陕西省

梅斯管理员

#R-CHOP# #DLBCL#

【Cancer Treat Rev】DLBCL中改良R-CHOP的路线图

2024-02-20发表于上海

梅斯管理员

#DLBCL# #CAR-T# #弥漫大B细胞淋巴瘤#

【EHO】R/R DLBCL患者CAR-T治疗失败后异基因移植的结局

2024-01-31发表于陕西省

梅斯管理员

#DLBCL# #弥漫大B细胞淋巴瘤#

【Cancer Lett】CD30在EBV+DLBCL中高表达的调控机制及其影响预后的分子机制

2024-01-26发表于陕西省

梅斯管理员

#流行病学# #弥漫性大B细胞淋巴瘤# #DLBCL#

【Semin Hematol】弥漫性大B细胞淋巴瘤的流行病学和病原学

2024-01-24发表于陕西省

梅斯管理员

#CD47# #弥漫性大B细胞淋巴瘤# #DLBCL#

【Clin Transl Med】赵维莅教授团队证实CD47过表达与DLBCL微环境和进展的关系

2024-01-13发表于陕西省

cathymary

#DLBCL#

ESMO 2022：奥布替尼联合R-CHOP治疗既往未经治疗的non-GCB DLBCL患者的疗效和安全性

2022-09-13

cathymary

#DLBCL#

ESMO 2022：基于机器学习预测弥漫大B细胞淋巴瘤(DLBCL)患者的生发中心、MYC/BCL2蛋白双表达状态以及MYC基因重排的情况（LYSA研究）

2022-09-13

cathymary

#DLBCL#

Blood Cancer J：R-CEOP是不适合蒽环类DLBCL患者一线治疗的首选？

2022-09-10

cathymary

#DLBCL#

≥70岁DLBCL患者的临床特征和生存结局，来自中国多中心研究

2022-08-12

cathymary

#DLBCL#

【Blood Adv】rrDLBCL患者的基因突变谱及对CAR-T治疗的疗效

2022-08-06

cathymary

#DLBCL#

ASH 2021：二线 Axicabtagene Cilouleucel 治疗复发/难治DLBCL，疗效更佳

2021-12-28

cathymary

#DLBCL#

Blood Cancer J：大剂量甲氨蝶呤可有效预防DLBCL患者孤立性CNS复发

2021-08-25

cathymary

#DLBCL#

瑞基仑赛（Relma-cel）对于R/R DLBCL患者表现出突破性疗效

2021-07-26

cathymary

#DLBCL#

Int J Clin Oncol：tisagenlecleucel可有效且安全的治疗某些特定的日本R/R DLBCL患者

2021-06-08

cathymary

#DLBCL#

Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型

2021-05-27

cathymary

#DLBCL#

Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！

2021-05-15